Sales for the year to December 31, 2007 were US$66.8 million, an increase of 25% compared to the same period in 2006 (2006: US$53.3 million). Expressed in transaction currencies (XAGRID is primarily sold in Euros and Pounds sterling), sales increased by 15% due to growth in many of Shire's existing markets, with exchange rate movements against the US dollar accounting for the remaining 10% increase.
Human Genetic Therapies
REPLAGAL - Fabry disease
Sales for the year to December 31, 2007 were US$143.9 million, an increase of 22% compared to the same period in 2006 (2006: US$117.7 million). Expressed in transaction currencies (REPLAGAL is primarily sold in Euros and Pounds sterling) sales increased by 13% due to higher unit sales in Europe and Canada and the continued roll out of REPLAGAL to new countries, including those in Latin America, with REPLAGAL now approved in 41 countries (including Japan). Exchange rate movements against the US dollar accounted for the remaining 9% increase in sales.
ELAPRASE - Hunter syndrome
Sales for the year to December 31, 2007 were US$181.8 million (2006: US$23.6 million). Sales growth in 2007 was driven primarily by a full year of sales in the US (ELAPRASE was launched in the US in August 2006), sales in Europe (ELAPRASE was launched in several European markets in the first half of 2007), and pre-approval sales in several Latin American markets. ELAPRASE was approved for sale and marketing in Japan in October 2007 and is now approved for marketing and commercial distribution in 38 countries worldwide.
Royalty revenue increased by 2% to US$247.2 million for the year to
December 31, 2007 (2006: US$242.9 million).
Year to December 31, 2007 2006 Change
US$M US$M %
__________ __________ __________
|SOURCE Shire plc|
Copyright©2008 PR Newswire.
All rights reserved